Rua Bioscience Limited — Director's Dealing 2021

Jun 8, 2021

==> picture [91 x 27] intentionally omitted <==

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

==> picture [468 x 607] intentionally omitted <==

----- Start of picture text ----- To NZX Limited; andName of listed issuer: Rua Bioscience Limited ( Rua )Date this disclosure made: 8-Jun-21Date of last disclosure: 22-Apr-21Director or senior manager giving disclosureFull name(s): Manu CaddieName of listed issuer: Rua Biosicence LimitedName of related body corporate (if applicable):Kaihautu - Head of Innovation andPosition held in listed issuer:Regulation of RuaSummary of acquisition or disposal of relevant interest (excluding specified derivatives)Class of affected quoted financial products: Ordinary shares in RuaManu is a director and 50%shareholder of New ZealandNutraceuticals Limited ( NZNL ). NZNL isa limited partner of Hikurangi BioactivesLimited Partnership ( HBLP ) with a 40%economic interest in HBLP. HBLP is theNature of the affected relevant interest(s):registered holder and beneficial ownerof 22,108,787 (before the transaction)and 17,616,591 (after the transaction)ordinary shares in Rua.For that relevant interest-Number held in class before acquisition or disposal: 8,843,515Number held in class after acquisition or disposal: 7,046,636Current registered holder(s): HBLPRegistered holder(s) once transfers are registered: HBLPSummary of acquisition or disposal of specified derivatives relevant interest (if applicable)Type of affected derivative: N/AClass of underlying financial products: N/ADetails of affected derivative-The notional value of the derivative (if any) or the notional amount of underlying financialproducts (if any): N/AA statement as to whether the derivative is cash settled or physically settled: N/AMaturity date of the derivative (if any): N/AExpiry date of the derivative(if any): N/AThe price specified in the terms of the derivative (if any): N/AAny other details needed to understand how the amount of the consideration payableunder the derivative or the value of the derivative is affected by the value of the underlyingfinancial products: N/AFor that derivative,-Parties to the derivative: N/AIf the director or senior manager is not a party to the derivative, the nature of the relevantinterest in the derivative: N/ADetails of transactions giving rise to acquisition or disposalTotal number of transactions to which notice relates: 1----- End of picture text -----

Details of transactions requiring disclosure-

Date of transaction: Nature of transaction:

Name of any other party or parties to the transaction (if known):

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

Number of financial products to which the transaction related:

4-Jun-21 Off-market sale Unknown NZ$664,844.80 being 40% of proceeds of HBLP's sale of 4,492,196 shares for $1,662,112 (before fees)

1,796,878 (being 40% of 4,492,196)

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period: Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

No N/A N/A

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

Nature of relevant interest:

Options that are convertible to ordinary shares in Rua under Rua's employee share option plan

Entitlement to become legal and beneficial owner subject to the meeting of vesting and other terms and conditions under Rua's employee share option plan

For that relevant interest,-

Number held in class: Current registered holder(s):

For a derivative relevant interest,- Type of derivative:

55,000 options potentially convertible to 283,072 ordinary shares

N/A N/A

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

For that derivative relevant interest,-

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

N/A N/A N/A N/A N/A N/A N/A N/A N/A

Certification

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer: Date of signature: or Signature of person authorised to sign on behalf of director or officer:

==> picture [35 x 41] intentionally omitted <==

8/06/21

Date of signature: Name and title of authorised person: